Semaglutide Dosage Protocol

The STEP 1 trial randomized 1,961 adults with obesity to semaglutide 2.4 mg weekly or placebo and reported a mean body weight reduction of 14.9% at 68 weeks, compared with 2.4% for placebo [1]. Semaglutide is a 31-amino-acid GLP-1 receptor agonist engineered with a C-18 fatty diacid side chain that enables albumin binding and a circulating half-life near 165 hours [2].

Reported protocols in the peer-reviewed literature follow a strict 16-week titration from 0.25 mg weekly to a maintenance dose of either 1.0 mg (type 2 diabetes, Ozempic label) or 2.4 mg (chronic weight management, Wegovy label), with off-label compounded variants hewing closely to these same titration curves [1,3].

How Semaglutide Works: Mechanism of Action

In short: semaglutide mimics a short-lived gut hormone that tells the brain you're full and tells the pancreas to release more insulin — but it's engineered to hang around in the blood for a week instead of a few minutes.

Semaglutide is a long-acting analogue of glucagon-like peptide-1 (GLP-1), a 30-amino-acid incretin hormone released by intestinal L cells in response to nutrient ingestion. Two amino-acid substitutions (Aib8 and Arg34) confer resistance to dipeptidyl peptidase-4 (DPP-4) cleavage, while a lysine-26 fatty diacid linker enables reversible, non-covalent albumin binding [2].

The resulting molecule is shielded from renal clearance and DPP-4 degradation, producing an effective terminal half-life of approximately 7 days that supports once-weekly subcutaneous administration.

At the receptor level, semaglutide is a full agonist of the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor expressed in pancreatic beta cells, hypothalamic and hindbrain neurons, gastric smooth muscle, and cardiac endothelium [2]. Receptor activation enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, delays gastric emptying, and reduces central appetite drive via projections to the arcuate and paraventricular nuclei.

The SUSTAIN 6 cardiovascular outcomes trial (n = 3,297; median follow-up 2.1 years) reported a 26% relative risk reduction in major adverse cardiovascular events (hazard ratio 0.74, 95% CI 0.58–0.95) for semaglutide 0.5–1.0 mg weekly in patients with type 2 diabetes and high cardiovascular risk [4]. The SELECT trial later extended this cardioprotective signal to a non-diabetic, overweight/obese population, with a 20% reduction in MACE on semaglutide 2.4 mg weekly [5].

Pharmacokinetic steady state is reached after approximately 4 to 5 weeks of fixed dosing, which is the rationale for the mandatory 4-week titration intervals in the approved label. Area under the curve scales linearly with dose across the 0.25–2.4 mg weekly range [2]. Bioavailability after subcutaneous injection is 89%, and exposure is similar across injection sites (abdomen, thigh, upper arm). Renal impairment up to stage 4 CKD does not require dose adjustment, as semaglutide is primarily cleared by proteolytic degradation rather than renal filtration.

Semaglutide Dose Ranges in the Peer-Reviewed Literature

In short: diabetes maintenance doses are 0.5–1.0 mg weekly; weight-loss maintenance is 2.4 mg weekly; every pivotal trial used the same mandatory step-up schedule.

Reported pivotal-trial protocols share a common architecture: a mandatory 4-week 0.25 mg weekly "initiation" phase to attenuate gastrointestinal side effects, followed by sequential 4-week dose-doubling steps until the target maintenance dose is reached [1,3,4]. The 2.4 mg weight-management dose requires the longest titration at 16 weeks, while the 1.0 mg diabetes dose completes in 8 weeks.

Oral semaglutide (Rybelsus) uses a fundamentally different dosing paradigm: daily administration in the fasted state, taken with no more than 120 mL of water, followed by a 30-minute fast before any food, drink, or other oral medication. This is required because semaglutide is co-formulated with the absorption enhancer SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate), and gastric pH must remain elevated for absorption [6]. Bioavailability is approximately 1% even under optimal conditions.

Compounded semaglutide is not covered by published pivotal-trial data. Survey reports from telehealth cohorts describe protocols that mirror the approved label titration, though with higher reported deviation from the 4-week interval schedule. Compounded products are frequently supplied as multi-dose vials requiring user reconstitution, which introduces dosing error risk absent from the pre-filled pens used in trials.

Semaglutide Reconstitution: Math and Worked Examples

In short: how much BAC water you add determines how many "units" on an insulin syringe equals your target mg dose. Get the math wrong and you're off by a factor of 2 to 4.

Compounded semaglutide typically ships as lyophilized powder in 2 mg, 5 mg, or 10 mg vials. Bacteriostatic water (BAC water, 0.9% benzyl alcohol) is the standard diluent.

Formula: Concentration (mg/mL) = Vial peptide (mg) ÷ BAC water added (mL)

Worked example — 5 mg vial with 2 mL BAC water (the most common consumer-market configuration):

• Final concentration: 5 mg ÷ 2 mL = 2.5 mg/mL
• For a 0.25 mg titration dose: 0.25 mg ÷ 2.5 mg/mL = 0.10 mL = 10 units on a U-100 insulin syringe
• For a 0.5 mg dose: 0.5 mg ÷ 2.5 mg/mL = 0.20 mL = 20 units
• For a 1.0 mg dose: 1.0 mg ÷ 2.5 mg/mL = 0.40 mL = 40 units
• For a 2.4 mg dose: 2.4 mg ÷ 2.5 mg/mL = 0.96 mL = 96 units

10 mg vial with 2 mL BAC water (higher concentration, smaller injection volume):

• Final concentration: 5 mg/mL
• 0.25 mg = 0.05 mL = 5 units
• 2.4 mg = 0.48 mL = 48 units

2 mg vial with 1 mL BAC water (lowest-concentration configuration):

• Final concentration: 2 mg/mL
• 0.25 mg = 0.125 mL = 12.5 units (requires syringe with half-unit markings)

Reconstituted semaglutide is stable under refrigeration (2–8 °C) for approximately 28 to 56 days according to manufacturer stability data on the pre-filled pens [2]. Compounded vials reconstituted with BAC water have been reported stable for similar windows, though independent stability data for compounded products is sparse.

Semaglutide Administration, Titration, and Dosing Schedule

In short: subcutaneous, weekly, same day each week; oral Rybelsus has strict fasting rules that matter for absorption.

Semaglutide is administered subcutaneously. Injection sites used in the STEP and SUSTAIN trials were the abdomen (excluding a 5 cm radius around the umbilicus), anterior thigh, and upper outer arm [1,3]. No meaningful pharmacokinetic difference between sites was observed, so site rotation is a skin-tolerability consideration rather than an absorption one.

Injections use a 29–31 gauge, 4–6 mm insulin syringe at a 90-degree angle. Because the injection volume is small (typically 5–50 units on a U-100 scale), aspiration is not required and intramuscular administration is unlikely at these needle lengths. The trials did not specify a fixed time of day; most protocols describe a consistent day-of-week dosing schedule to maintain steady-state exposure.

Titration between maintenance doses followed a fixed 4-week interval in every pivotal trial [1,3,4]. If a dose is delayed by more than 2 days in Ozempic/Wegovy labeling, the next dose is administered on the originally scheduled day; if more than 5 days have elapsed, the dose is skipped and resumed at the next scheduled interval. These rules derive from semaglutide's 7-day half-life: a delay greater than 5 days approaches two half-lives of washout and reinitiation at the previous dose may exceed current tolerance.

Oral semaglutide (Rybelsus) has distinct administration requirements: the 3 mg tablet is taken in the morning, on an empty stomach, with no more than 120 mL of plain water, and at least 30 minutes must elapse before any food, other beverages, or additional oral medications [6]. Deviation from this window substantially reduces absorption.

Concurrent administration with sulfonylureas or insulin increases hypoglycemia risk and typically prompts a dose reduction of the concurrent agent at semaglutide initiation, per SUSTAIN trial protocols [4].

Semaglutide Cycle Structure and Protocol Duration

In short: semaglutide is chronic therapy, not a cycle. Stop it and most of the weight comes back within a year.

Pivotal trials treated semaglutide as chronic therapy rather than a cycled protocol. STEP 1 ran 68 weeks with no planned washout [1]. STEP 4 examined discontinuation effects: participants who switched from semaglutide 2.4 mg to placebo at week 20 regained two-thirds of lost weight by week 68, indicating that therapeutic effects on body weight are not durable after withdrawal and that chronic administration is required to maintain benefit [8].

The SUSTAIN 6 cardiovascular outcomes trial dosed patients for a median of 2.1 years without scheduled interruption [4]. SELECT continued to a median 3.3 years [5]. No clinical-trial data support planned "cycling" of semaglutide, and tolerance at the GLP-1 receptor has not been observed within trial durations of up to 4 years.

Titration pauses are described in the label for patients who cannot tolerate escalation. When nausea, vomiting, or other GI side effects prevent advancement to the next step, maintaining the current dose for an additional 4 weeks or returning to the previous step is described in clinical-use case series.

Discontinuation considerations include a 5- to 6-week period of residual receptor activity following the final dose (approximately five half-lives). Weight regain typically begins within weeks of the last injection and progresses over 6–12 months [8].

Semaglutide Side Effects and Safety Profile

In short: nausea, diarrhea, vomiting, and constipation during titration hit roughly 25-45% of users; serious events are rare but include pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumors.

Gastrointestinal side effects dominate the semaglutide adverse-event profile. In STEP 1, nausea was reported by 44.2% of the semaglutide 2.4 mg arm (vs. 16.1% placebo), diarrhea by 31.5% (vs. 15.9%), vomiting by 24.8% (vs. 6.6%), and constipation by 23.4% (vs. 9.5%) [1]. These events were generally mild to moderate and concentrated during the titration phase, with incidence declining at maintenance dosing.

Serious adverse events in pivotal trials included acute pancreatitis (0.2–0.4% across STEP, SUSTAIN, and SELECT — not statistically elevated over placebo in most analyses), cholelithiasis/cholecystitis (2.6% in STEP 1 vs. 1.2% placebo), and acute kidney injury in the setting of severe volume depletion from GI losses [1,4,5].

The FDA label carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity data (MTC/medullary thyroid carcinoma in rats). Personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia type 2 (MEN 2) are contraindications [2]. Diabetic retinopathy worsening was reported in SUSTAIN 6 (3.0% vs. 1.8% placebo) and is considered in patients with pre-existing proliferative retinopathy [4].

Contraindications and cautions include pregnancy (animal teratogenicity; washout of at least 2 months before planned conception is described in the label), severe gastroparesis, history of pancreatitis, and concurrent use with other GLP-1 receptor agonists. Drug interactions are limited by semaglutide's peptide nature, but delayed gastric emptying can alter absorption of oral medications with narrow therapeutic index.

Semaglutide Vendor Ratings: Who Publishes Lab Data at ≥99% Purity?

Which semaglutide vendors publish lab data ≥99% purity?

TriedRx aggregates publicly available third-party lab reports (HPLC, mass spectrometry, endotoxin testing), transparency disclosures, reputation signals, and operational data from 84 U.S.-accessible semaglutide vendors — then grades them on a transparent rubric. We do not run our own chromatography and do not test samples ourselves. Compounded and research-chem semaglutide is an especially variable market: published lab reports we have reviewed show peptide content ranging from roughly 61% to 104% of labeled mass across vendors, and bacterial endotoxin has exceeded USP limits in a measurable subset of reported lots. No vendor pays for inclusion; we accept no vendor-submitted samples or sponsored placement.

See all 84 semaglutide vendors we rate → /brands?peptide=semaglutide

Related: Semaglutide Research Profile and Vendor Rankings

For full research background on semaglutide, including the STEP and SUSTAIN trial program summaries, the compounded-semaglutide market analysis, and the aggregated third-party lab data we have compiled across 920 lot reports from 84 vendors, see the TriedRx semaglutide profile. Related content includes the GLP-1 Peptide Category Guide and the dosing protocols for tirzepatide and liraglutide.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185. DOI: 10.1056/NEJMoa2032183.

1. Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-80. PMID: 26308095. DOI: 10.1021/acs.jmedchem.5b00726.

1. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PMID: 33667417. NCT03552757.

1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6). N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186.

1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131. NCT03574597.

1. Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy. Diabetes Care. 2019;42(9):1724-1732. PMID: 31160495.

1. Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS). N Engl J Med. 2022;387(24):2245-2257. PMID: 36322843.

1. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425. PMID: 33755728.